IMNM vs ZYME
IMNM: A clinical-stage oncology biotech advancing first-in-class and best-in-class targeted cancer therapies, including varegacestat for desmoid tumors and a pipeline of antibody-drug conjugates for solid tumors and hematologic malignancies. ZYME: A biotech company pioneering multispecific antibodies and ADCs for cancer and autoimmune disease, monetizing through a partnership-driven royalty aggregation model while advancing an internal pipeline.
Side-by-side fundamentals
| Metric | IMNM | ZYME | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $22.58 | $22.71 | |
| Market cap as of 2026-07-31 | $2.6B | $1.7B | |
| Net margin as of 2026-07-31 | -1687.1% | -126.3% | ZYME higher |
| Operating margin as of 2026-07-31 | -1784.1% | -140.3% | ZYME higher |
| ROE as of 2026-07-31 | -51.1% | -37.8% | ZYME higher |
| ROA as of 2026-07-31 | -47.3% | -25.2% | ZYME higher |
| Debt / equity as of 2026-07-31 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-31 | -63.3% | +3.3% | ZYME higher |
| Revenue CAGR (3y) SEC XBRL | -29.6% | -36.4% | IMNM higher |
| Beta as of 2026-07-31 | 2.08 | 0.85 | |
| 1-year return as of 2026-07-27 close | +107.7% | +75.5% | IMNM higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.